Expressive Wealth LLC Makes New $868,000 Investment in Gilead Sciences, Inc. $GILD

Expressive Wealth LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, Holdings Channel reports. The institutional investor acquired 6,869 shares of the biopharmaceutical company’s stock, valued at approximately $868,000. Gilead Sciences accounts for 0.8% of Expressive Wealth LLC’s portfolio, making the stock its 26th largest holding.

Other large investors have also recently made changes to their positions in the company. BlackRock Inc. purchased a new position in Gilead Sciences in the second quarter valued at $15,393,785,000. Norges Bank purchased a new stake in shares of Gilead Sciences during the 4th quarter worth about $2,617,152,000. Deutsche Bank AG purchased a new stake in shares of Gilead Sciences during the 2nd quarter worth about $918,387,000. Boston Partners acquired a new stake in shares of Gilead Sciences during the 4th quarter valued at about $517,808,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Gilead Sciences during the 2nd quarter valued at about $398,905,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on GILD shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 price target on shares of Gilead Sciences in a report on Wednesday, August 5th. Morgan Stanley lowered their price target on Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating on the stock in a research report on Monday, July 27th. Daiwa Securities Group dropped their price objective on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, May 19th. Barclays cut their price objective on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 29th. Finally, Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a research note on Wednesday, May 20th. Twenty-four equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $158.04.

Gilead Sciences Stock Up 1.9%

GILD stock opened at $146.12 on Friday. Gilead Sciences, Inc. has a 52 week low of $108.46 and a 52 week high of $157.29. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The firm has a 50-day simple moving average of $131.97 and a 200-day simple moving average of $136.59. The stock has a market capitalization of $181.18 billion, a P/E ratio of -54.73 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. During the same period last year, the company posted $2.01 EPS. Gilead Sciences’s quarterly revenue was up 10.6% compared to the same quarter last year. Equities analysts forecast that Gilead Sciences, Inc. will post -0.51 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. Gilead Sciences’s dividend payout ratio is presently -122.85%.

Insider Transactions at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the completion of the sale, the director directly owned 10,066 shares in the company, valued at approximately $1,459,771.32. The trade was a 33.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $138.36, for a total value of $415,080.00. Following the completion of the transaction, the chief financial officer directly owned 165,646 shares of the company’s stock, valued at approximately $22,918,780.56. This represents a 1.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 87,000 shares of company stock worth $11,562,960. 0.30% of the stock is owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.